Migraine Drug Ubrogepant Shows Promise in Alleviating Early Symptoms
By Fred Schwaller & Nature magazine
A recent phase 3 clinical trial has revealed promising results regarding the use of ubrogepant, a drug typically used to treat migraine headaches. The study suggests that taking ubrogepant at the first sign of an oncoming migraine can potentially prevent preheadache symptoms such as fatigue and light sensitivity.
The trial, published in Nature Medicine, highlighted the drug’s ability to address prodrome symptoms that occur before the onset of a full-blown migraine attack. These symptoms can include fatigue, brain fog, light sensitivity, neck pain, and difficulty concentrating. According to Peter Goadsby, a neuroscientist at King’s College London and co-author of the study, ubrogepant could offer relief from this debilitating phase of a migraine.
During the trial, 438 participants who could identify the early signs of a migraine attack took ubrogepant or a placebo when they felt prodromal symptoms coming on. The results showed that for some participants, the drug improved their ability to concentrate one hour after treatment, reduced light sensitivity after two hours, and alleviated fatigue and neck pain after three hours.
While the effects of ubrogepant were modest, with an increase of up to 15 percentage points compared to the placebo, the study confirmed that the drug can be effective when dosed early in the migraine process. Goadsby emphasized the importance of understanding one’s migraine symptoms to benefit from ubrogepant’s potential.
Ubrogepant works by blocking receptors that bind to calcitonin gene-related peptide (CGRP), a molecule involved in migraine attacks. The study could provide valuable insights into the mechanistic understanding of migraines and how targeting CGRP receptors early on may help in managing symptoms.
Overall, the findings suggest that ubrogepant has the potential to address non-headache symptoms associated with migraines when taken at the first sign of an attack. As further research explores the drug’s efficacy in different stages of migraines, it may pave the way for improved treatments and management strategies for individuals experiencing these debilitating headaches.
